Hemodialysis Vascular Grafts Market Report Scope & Overview:

The Hemodialysis Vascular Grafts Market was valued at USD 269.80 Million in 2025 and is expected to reach USD 433.27 Million by 2035, growing at a CAGR of 4.85% from 2026-2035.

The Hemodialysis Vascular Grafts Market supplies the synthetic and biologic conduits that surgeons place when a patient's own veins cannot support a durable arteriovenous fistula for dialysis access. Demand tracks the growing population of patients reaching end-stage kidney disease each year, many of whom exhaust fistula options after repeated cannulation and turn to a graft as a bridge or a long-term solution. Manufacturers compete on patency duration, infection resistance and how soon after implantation a graft can be safely needled, with early-cannulation designs narrowing the gap with surgical fistulas on time to first use. Hospitals remain the primary purchasing channel, though dialysis centers are taking on a larger share of graft surveillance as care shifts outside acute settings.

⮞In March 2026, the U.S. Centers for Disease Control and Prevention reported that about 831,000 people were living with end-stage kidney disease in 2023, with 67% receiving dialysis. A patient population of that size sustains steady, if unspectacular, demand for vascular access devices regardless of short-term economic conditions.

U.S. Hemodialysis Vascular Grafts Market Outlook:

The U.S. Hemodialysis Vascular Grafts Market was valued at USD 84.95 Million in 2025 and is expected to reach USD 133.22 Million by 2035, growing at a CAGR of 4.60% from 2026-2035.

The U.S. Hemodialysis Vascular Grafts Market is the largest national market within North America, supported by the country's large dialysis-dependent population and an established base of vascular surgeons experienced in graft placement. Reimbursement policy under the Medicare End-Stage Renal Disease program shapes which devices centers adopt, since outpatient facilities weigh a product's purchase cost against the payment code attached to its use. Hospitals continue to place the majority of grafts, particularly for patients with central vein complications, while dialysis centers increasingly manage surveillance and minor revisions under separate access-maintenance programs. Growth is modest but dependable, tracking the country's aging dialysis population more closely than any single product cycle or competitive launch.

⮞In November 2025, Merit Medical Systems withdrew its CMS Transitional Pass-Through payment application for its Wrapsody cell-impermeable endoprosthesis and began full U.S. commercialization instead. The decision shows how a reimbursement setback can still leave a vascular access device with a viable, if slower, path to U.S. adoption.

By Material, PTFE Dominates the Hemodialysis Vascular Grafts Market and Biosynthetic Grows Fastest

Polytetrafluoroethylene holds the largest material share because decades of surgical familiarity, predictable handling characteristics and a well-understood complication profile make it the default choice when a fistula is not viable. Surgeons trained on PTFE grafts can place and revise them using established techniques, and hospital purchasing committees favor a material with a long track record over newer alternatives with thinner clinical histories. Supply from multiple established manufacturers also keeps PTFE grafts available across price tiers, reducing the purchasing risk that comes with relying on a single proprietary material.

Biosynthetic materials are growing fastest as bioengineered vessel candidates advance through late-stage trials aimed at patients who repeatedly fail fistula maturation. These materials promise better resistance to infection and, in some designs, the ability to self-seal after repeated needle punctures, addressing two of the most common reasons a graft fails. Centers treating higher-risk patients are watching this category closely because a biosynthetic option that outperforms PTFE on durability could change purchasing patterns well before it captures a large share of total volume.

⮞In November 2025, Humacyte presented two-year data from its V007 Phase 3 trial at Kidney Week 2025, showing its bioengineered vessel sustained longer use than autogenous fistula in high-need dialysis subgroups. The result strengthens the case for biosynthetic materials among patients who have already exhausted fistula options.

By Configuration, Conventional Grafts Dominates the Hemodialysis Vascular Grafts Market and Early-Cannulation Grafts Grows Fastest

Conventional graft configurations retain the largest share because they remain the lowest-cost, most widely stocked option across hospitals and surgical centers, and most patients can tolerate the standard maturation period before first use. Surgeons default to conventional designs when a patient has no urgent need to begin dialysis through the new access, reserving premium configurations for cases where timing is a real clinical constraint. Established reimbursement coding for conventional placement also removes a layer of administrative uncertainty that newer configurations can still carry.

Early-cannulation grafts are growing fastest because they let clinicians dialyze through the new access within days rather than weeks, which matters most for patients who need to avoid or remove a central venous catheter quickly. Catheters carry a materially higher infection risk than grafts, so any configuration that shortens catheter dependence attracts attention from infection-control and nephrology teams alike. As more centers adopt protocols built around rapid catheter removal, demand for early-cannulation designs is rising faster than for the broader graft category.

⮞In December 2025, researchers published a comparative clinical study of Flixene and Acuseal early-cannulation grafts in the Journal of Vascular Surgery. The Taiwan-based study evaluated 152 graft procedures, identifying differences in secondary patency, bleeding and graft delamination between the two configurations.

By End User, Hospitals Dominates the Hemodialysis Vascular Grafts Market and Dialysis Centers Grows Fastest

Hospitals account for the largest end-user share because graft placement is a surgical procedure that requires an operating room, anesthesia support and the ability to manage complications such as bleeding or infection on site. Patients with central vein stenosis or other complex vascular anatomy are referred to hospital-based vascular surgeons rather than outpatient settings, concentrating the more difficult and often more expensive cases within the hospital channel. This keeps hospitals as the primary purchasing decision-maker for the devices used in graft placement.

Dialysis centers are the fastest-growing end-user group as more of the ongoing surveillance, minor revision and access-maintenance work shifts to outpatient settings equipped for interventional procedures. Centers that can manage a failing graft without sending the patient back to a hospital reduce cost and disruption for both the provider and the patient. Equipment reliability at these centers has become a visible concern following recent recalls affecting dialysis-related hardware, which is pushing centers to scrutinize device quality as closely as placement outcomes.

⮞In August 2025, the UK Kidney Association published its updated Clinical Practice Guideline on Vascular Access for Haemodialysis. The guideline addresses routine arteriovenous access care, graft configurations, cannulation and complication management, providing updated clinical guidance for dialysis-center professionals.

By Graft Site, Upper Arm Dominates the Hemodialysis Vascular Grafts Market and Thigh Grows Fastest

Upper arm placement holds the largest share because it offers larger-caliber vessels than the forearm, supports higher blood flow for effective dialysis and remains accessible even in patients who have already used forearm sites for a prior fistula or graft. Surgeons generally move proximally along the arm as earlier access sites fail, making the upper arm the most common site once forearm options are exhausted. Its central position in standard surgical site-selection protocols keeps upper arm placement ahead of other anatomic locations in overall volume.

Thigh placement is growing fastest as more patients outlive their upper body access options after years of recurring graft failure and site exhaustion. Thigh grafts carry a higher recognized risk of infection and limb complications than upper body sites, so surgeons reserve them for patients with no remaining alternative, but that pool is expanding as dialysis populations age and survive longer on treatment. Specialized surgical training in thigh graft placement is becoming a differentiator for vascular surgery programs serving these complex, access-exhausted patients.

Regional Analysis:

North America Hemodialysis Vascular Grafts Market Insights

With a share of 36.40% in 2025, North America led the market, supported by the United States' large dialysis-dependent population, established vascular surgery capacity and a Medicare reimbursement structure that, while not generous toward newer device categories, still sustains predictable procedure volume. Canada contributes a smaller, steady share through its public dialysis infrastructure. Device companies based in the region continue to expand their access-device portfolios through bolt-on acquisitions of smaller, clinically focused developers rather than large transformational deals, reflecting the market's slow but durable growth profile.

Competitive activity in the region centers on incremental product differentiation, since the core graft materials have changed little in recent years while delivery systems, coatings and configuration options continue to evolve. Consolidation among device makers has reduced the number of independent access-device companies, concentrating hospital purchasing relationships among a smaller group of established suppliers. This dynamic is expected to keep North America ahead on both procedure volume and device innovation through 2035, even as growth in absolute dollar terms remains modest compared with faster-expanding regions.

⮞In December 2025, the United States Renal Data System published its 2025 Annual Data Report, documenting changes in hemodialysis vascular access utilization. The report found that AV graft use at dialysis initiation increased from 2.4% in 2021 to 3.9% in 2024, indicating a gradual recovery in graft utilization.

Asia Pacific Hemodialysis Vascular Grafts Market Insights

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 6.95% from 2026 to 2035, as Japan, China, India and South Korea manage rapidly growing dialysis populations with healthcare systems that are still building out dedicated vascular access infrastructure. Japan's large, well-documented dialysis population gives device makers a mature reference market within the region, while China and India represent the larger unmet opportunity as dialysis capacity expands into smaller cities. Government health insurance expansion in several countries is gradually extending coverage to vascular access procedures that were previously paid out of pocket.

Local manufacturing capacity for dialysis consumables is growing faster than for surgical-grade grafts, which still rely heavily on imports from established Western and Japanese suppliers in most Asia Pacific markets. Price sensitivity among public hospital systems favors lower-cost conventional grafts over premium early-cannulation or biosynthetic options, slowing the regional mix shift seen in North America and Europe. Even so, the sheer scale of the growing dialysis population is expected to keep Asia Pacific the fastest-growing region through 2035 as access to nephrology care continues to expand.

Europe Hemodialysis Vascular Grafts Market Insights

Europe is the second largest region in the market, with Germany, the United Kingdom, France and Italy hosting established vascular access programs within national health systems that place a strong emphasis on standardized surgical protocols. Large dialysis providers headquartered in the region operate extensive outpatient center networks across multiple countries, giving them unusual influence over which device categories individual centers adopt compared with the more fragmented hospital-driven purchasing seen in other regions. This structure has made Europe an early testing ground for bioengineered vessel candidates seeking a path to broader adoption.

Centralized health technology assessment processes in several European countries can delay adoption of newer, higher-cost device categories even after regulatory approval, since reimbursement committees require demonstrated cost-effectiveness before expanding coverage. Currency and procurement differences across the region's many national health systems complicate pan-European pricing strategies for device makers. These factors keep Europe a steady but slower-growing contributor to the market relative to Asia Pacific, with adoption of next-generation access technologies typically following, rather than leading, developments in the United States.

MEA & Latin America Hemodialysis Vascular Grafts Market Insights

The Middle East and Africa remains a smaller market, with Saudi Arabia and the United Arab Emirates building dedicated dialysis infrastructure as part of broader healthcare investment, while South Africa offers the region's most established vascular surgery training base. Limited specialized surgical capacity in much of the region means many patients rely on central venous catheters longer than clinical guidelines recommend, since graft placement requires surgeons and operating capacity that remain concentrated in a handful of urban centers. Expanding dialysis coverage under national health insurance programs is gradually increasing the population eligible for graft placement rather than catheter-dependent care.

Latin America contributes a modest share, led by Brazil, where public and private dialysis networks are expanding access to surgical vascular access alongside catheter-based care. Argentina, Mexico and Colombia add smaller but growing demand as regional healthcare investment increases. Import dependence for surgical-grade grafts, currency volatility and uneven distribution of vascular surgery expertise outside major cities constrain faster adoption. Expanding public health coverage for chronic kidney disease treatment across the region is expected to support steady, if gradual, growth in graft placement through 2035.

⮞In October 2025, researchers from King Faisal University and collaborating Saudi healthcare institutions published a multicenter study examining permanent vascular access patterns among hemodialysis patients in Al-Ahsa. Among 378 patients, only two used arteriovenous grafts, highlighting limited graft utilization in the investigated population.

Market Dynamics:

Growth Drivers: Rising dialysis populations and improving procedural outcomes are sustaining steady device demand

The most direct supportive factor is the growing number of patients reaching end-stage kidney disease each year, a population that continues to expand as diabetes and hypertension rates rise globally and as more people survive long enough on dialysis to eventually exhaust their original fistula. Every patient who outlives a fistula or cannot form one in the first place becomes a candidate for a graft, giving the category a demand base that is largely independent of any single country's healthcare spending cycle. This structural supportive factor has kept the market growing steadily even through periods of broader medical device budget pressure.

A second supportive factor is clinical data showing that newer graft configurations and registry-based procedural techniques are improving outcomes for the hardest-to-treat patients. Vessel preparation systems used alongside standard angioplasty are demonstrating meaningful patency gains in registry studies, giving physicians more confidence in extending graft life through minimally invasive maintenance rather than early replacement. As more of this real-world evidence accumulates, physicians are more willing to recommend grafts over catheters for patients who were previously steered toward catheter-based access by default, widening the device's addressable patient pool.

⮞In 2025, VentureMed Group reported FLEX First AV registry results showing a 70% target lesion primary patency rate at six months when its vessel preparation system was used alongside standard angioplasty for dialysis access dysfunction. The data support a broader shift toward extending graft life through minimally invasive maintenance rather than early surgical replacement.

Restraints: Device recalls and slow-changing surgical practice limit faster adoption of newer designs

Device recalls tied to delivery systems and implantation hardware remain a persistent restraint, since even a recall unrelated to the graft material itself can slow a product's adoption while hospitals review alternative options and regulators complete their review. Purchasing committees tend to respond to a recall by broadening their approved supplier list rather than narrowing it, which protects overall market access but can erode the share of the specific product involved for an extended period. This dynamic rewards manufacturers with diversified portfolios over those dependent on a single flagship device.

Surgical practice also changes slowly in this category, since vascular surgeons trained on established techniques have limited incentive to switch materials or configurations absent a clear outcomes advantage, and hospital credentialing processes for new devices can take months to complete. Reimbursement coding for newer configurations sometimes lags their regulatory approval, leaving early adopters absorbing cost before payment structures catch up. Together, these forces keep the overall pace of category-wide material or configuration change much slower than in more dynamically priced areas of medical devices.

Opportunities: Reimbursement shifts and site-exhausted patients are opening new avenues for premium devices

Reimbursement policy changes create periodic openings for device makers willing to commercialize ahead of favorable payment codes, since a product that proves its clinical value in practice can build physician demand that eventually pressures payers to expand coverage. Centers that adopt a newer device early, even without full reimbursement support, can establish clinical experience and outcomes data that strengthens the case for broader payment policy changes down the line. This creates a opportunity for well-capitalized manufacturers to absorb short-term reimbursement friction in exchange for a durable first-mover position.

A second opportunity lies in the growing population of site-exhausted patients who have cycled through multiple fistulas and grafts and need specialized placement options such as thigh or central-vein-bypass configurations. These patients require more complex procedures and command premium pricing relative to standard upper arm or forearm grafts, rewarding manufacturers that maintain a full range of configurations rather than competing only on the standard product. As dialysis populations age and survive longer on treatment, this site-exhausted segment is expected to grow faster than the market overall.

⮞In November 2025, the Centers for Medicare & Medicaid Services finalized a 2.2% payment rate increase for the Calendar Year 2026 End-Stage Renal Disease Prospective Payment System. Incremental reimbursement increases of this kind gradually improve the economics of adopting higher-cost vascular access devices within outpatient dialysis settings.

Hemodialysis Vascular Grafts Market Key Players:

• W. L. Gore & Associates, Inc.

• Merit Medical Systems, Inc.

• Getinge AB (Atrium Medical Corporation)

• Humacyte, Inc.

• Xeltis

Hemodialysis Vascular Grafts Market Report Scope: